FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016098773> ?p ?o ?g. }

• W2016098773 endingPage "e71266" @default.
• W2016098773 startingPage "e71266" @default.
• W2016098773 abstract "The oral second-generation bis-aryl urea fms-like tyrosine kinase 3 (FLT3) inhibitor quizartinib (AC220) has favorable kinase selectivity and pharmacokinetics. It inhibits mutant and wild-type FLT3 in vivo at 0.1 and 0.5 µM, respectively, and has shown favorable activity and tolerability in phase I and II trials in acute myeloid leukemia, with QT prolongation as the dose-limiting toxicity. Co-administration with chemotherapy is planned. We characterized interactions of quizartinib with the ATP-binding cassette (ABC) proteins ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Its effects on uptake of fluorescent substrates and apoptosis were measured by flow cytometry, binding to ABCB1 and ABCG2 drug-binding sites by effects on [125I]iodoarylazidoprazosin ([125I]-IAAP) photolabeling and ATPase activity, and cell viability by the WST-1 colorimetric assay. Quizartinib inhibited transport of fluorescent ABCG2 and ABCB1 substrates in ABCG2- and ABCB1-overexpressing cells in a concentration-dependent manner, from 0.1 to 5 µM and from 0.5 to 10 µM, respectively, and inhibited [125I]-IAAP photolabeling of ABCG2 and ABCB1 with IC50 values of 0.07 and 3.3 µM, respectively. Quizartinib at higher concentrations decreased ABCG2, but not ABCB1, ATPase activity. Co-incubation with quizartinib at 0.1 to 1 µM sensitized ABCG2-overexpressing K562/ABCG2 and 8226/MR20 cells to ABCG2 substrate chemotherapy drugs in a concentration-dependent manner in cell viability and apoptosis assays. Additionally, quizartinib increased cellular uptake of the ABCG2 substrate fluoroquinolone antibiotic ciprofloxacin, which also prolongs the QT interval, in a concentration-dependent manner, predicting altered ciprofloxacin pharmacokinetics and pharmacodynamics when co-administered with quizartinib. Thus quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. These interactions should be considered in the design of treatment regimens combining quizartinib and chemotherapy drugs and in choice of concomitant medications to be administered with quizartinib." @default.
• W2016098773 created "2016-06-24" @default.
• W2016098773 creator A5037989073 @default.
• W2016098773 creator A5042855256 @default.
• W2016098773 creator A5045187901 @default.
• W2016098773 creator A5049910941 @default.
• W2016098773 creator A5049921066 @default.
• W2016098773 creator A5050699960 @default.
• W2016098773 creator A5081938413 @default.
• W2016098773 date "2013-08-14" @default.
• W2016098773 modified "2023-10-17" @default.
• W2016098773 title "The FLT3 Inhibitor Quizartinib Inhibits ABCG2 at Pharmacologically Relevant Concentrations, with Implications for Both Chemosensitization and Adverse Drug Interactions" @default.
• W2016098773 cites W1506423591 @default.
• W2016098773 cites W1546346721 @default.
• W2016098773 cites W1803435936 @default.
• W2016098773 cites W1964724251 @default.
• W2016098773 cites W1965659514 @default.
• W2016098773 cites W1971438689 @default.
• W2016098773 cites W1987561182 @default.
• W2016098773 cites W1990453662 @default.
• W2016098773 cites W1991953785 @default.
• W2016098773 cites W2000706147 @default.
• W2016098773 cites W2001852299 @default.
• W2016098773 cites W2003249638 @default.
• W2016098773 cites W2006960455 @default.
• W2016098773 cites W2007812119 @default.
• W2016098773 cites W2011187792 @default.
• W2016098773 cites W2012957144 @default.
• W2016098773 cites W2016883830 @default.
• W2016098773 cites W2018007736 @default.
• W2016098773 cites W201908734 @default.
• W2016098773 cites W2019490712 @default.
• W2016098773 cites W2020930633 @default.
• W2016098773 cites W2023695537 @default.
• W2016098773 cites W2025941747 @default.
• W2016098773 cites W2037302753 @default.
• W2016098773 cites W2041027929 @default.
• W2016098773 cites W2043216151 @default.
• W2016098773 cites W2044444556 @default.
• W2016098773 cites W2048146263 @default.
• W2016098773 cites W2061270171 @default.
• W2016098773 cites W2067532352 @default.
• W2016098773 cites W2070440937 @default.
• W2016098773 cites W2079967238 @default.
• W2016098773 cites W2091371557 @default.
• W2016098773 cites W2092401802 @default.
• W2016098773 cites W2098142549 @default.
• W2016098773 cites W2106742754 @default.
• W2016098773 cites W2112641034 @default.
• W2016098773 cites W2115030594 @default.
• W2016098773 cites W2115707319 @default.
• W2016098773 cites W2116137191 @default.
• W2016098773 cites W2123467745 @default.
• W2016098773 cites W2125213881 @default.
• W2016098773 cites W2125329951 @default.
• W2016098773 cites W2126572589 @default.
• W2016098773 cites W2129615499 @default.
• W2016098773 cites W2131308754 @default.
• W2016098773 cites W2135908929 @default.
• W2016098773 cites W2142830602 @default.
• W2016098773 cites W2145451520 @default.
• W2016098773 cites W2148467418 @default.
• W2016098773 cites W2150470057 @default.
• W2016098773 cites W2151121107 @default.
• W2016098773 cites W2155383511 @default.
• W2016098773 cites W2159147647 @default.
• W2016098773 cites W2161000665 @default.
• W2016098773 cites W2169120362 @default.
• W2016098773 cites W2171945016 @default.
• W2016098773 cites W2410172020 @default.
• W2016098773 cites W2467546275 @default.
• W2016098773 cites W2552548149 @default.
• W2016098773 cites W2588476685 @default.
• W2016098773 cites W2589076001 @default.
• W2016098773 doi "https://doi.org/10.1371/journal.pone.0071266" @default.
• W2016098773 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3743865" @default.
• W2016098773 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23967177" @default.
• W2016098773 hasPublicationYear "2013" @default.
• W2016098773 type Work @default.
• W2016098773 sameAs 2016098773 @default.
• W2016098773 citedByCount "27" @default.
• W2016098773 countsByYear W20160987732014 @default.
• W2016098773 countsByYear W20160987732015 @default.
• W2016098773 countsByYear W20160987732016 @default.
• W2016098773 countsByYear W20160987732017 @default.
• W2016098773 countsByYear W20160987732018 @default.
• W2016098773 countsByYear W20160987732019 @default.
• W2016098773 countsByYear W20160987732020 @default.
• W2016098773 countsByYear W20160987732021 @default.
• W2016098773 countsByYear W20160987732022 @default.
• W2016098773 countsByYear W20160987732023 @default.
• W2016098773 crossrefType "journal-article" @default.
• W2016098773 hasAuthorship W2016098773A5037989073 @default.
• W2016098773 hasAuthorship W2016098773A5042855256 @default.
• W2016098773 hasAuthorship W2016098773A5045187901 @default.
• W2016098773 hasAuthorship W2016098773A5049910941 @default.
• W2016098773 hasAuthorship W2016098773A5049921066 @default.
• W2016098773 hasAuthorship W2016098773A5050699960 @default.

• next